| Identification | Back Directory | [Name]
CLOZAPINE N-OXIDE | [CAS]
34233-69-7 | [Synonyms]
CLOZAPINE N-OXIDE
Clozapine N-oxide solution
Clozapine N-oxide Methanol Adduct
e)(1,4)diazepine,8-chloro-11-(4-methyl-1-piperazinyl)-5h-dibenzo(n-oxide
8-CHLORO-11-[4-METHYL-1-PIPERAZINYL]-5H-DIBENZO[B,E][1,4]DIAZEPINE N-OXIDE | [Molecular Formula]
C18H19ClN4O | [MDL Number]
MFCD00210190 | [MOL File]
34233-69-7.mol | [Molecular Weight]
342.82 |
| Chemical Properties | Back Directory | [Appearance]
Yellow Solid | [Melting point ]
190-248°C | [Fp ]
9℃ | [storage temp. ]
-20°C Freezer, Under Inert Atmosphere | [solubility ]
Soluble in DMSO. | [form ]
powder | [pka]
6.86±0.20(Predicted) | [color ]
Yellow | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. | [InChIKey]
OGUCZBIQSYYWEF-UHFFFAOYSA-N |
| Hazard Information | Back Directory | [Chemical Properties]
Yellow Solid | [Uses]
A 5-HT2 antagonist. A major metabolite of clozapine that can be monitored by HPLC. Possesses little or no activity towards serotonin receptors | [Description]
Clozapine-N-oxide (34233-69-7) is a clozapine?metabolite1?which is pharmacologically inert2. Agonist at human muscarinic designer receptors known as DREADDs, (designer receptors exclusively activated by designer drug).2?May be used to control grafted human pluripotent stem cell-derived neurons engineered to express DREADDs.3,4??Numerous other applications.5,6 | [Definition]
ChEBI: Clozapine N-oxide is a dibenzodiazepine. | [General Description]
Clozapine N-oxide (CNO), inactive from of clozapine drug, activates G-protein-coupled receptors (GPCRs). CNO serves as a synthetic ligand for engineered human muscarinic receptor. It elicits clozapine-like effects upon metabolic conversion. Clozapine conversion to CNO favors its passage through blood-brain barrier. | [Biochem/physiol Actions]
5-HT2 serotonin receptor antagonist; major metabolite of clopazine that can be monitored by HPLC. | [storage]
Room temperature (desiccate) | [References]
1) Eiermann?et al.?(1997),?The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine; Br. J. Clin. Pharmacol.,?44?439
2) Armbruster?et al.?(2007),?Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand; Proc. Natl. Acad. Sci. USA,?104?5163
3) Chen?et al.?(2016),?Chemical Control of Grafted Human PSC-Derived Neurons in a Mouse Model of Parkinson’s Disease; Cell Stem Cell,?18?817
4) Vazey and Aston-Jones (2014),?Designer receptors: therapeutic adjuncts to cell replacement therapy in Parkinson’s disease: J. Clin. Invest.,?124?2858
5) Gomez?et al.?(2017)?Chemogenetics revealed: DREADD occupancy and activation via converted clozapine; Science?357?503
6) Marcinkiewcz?et al. (2016)?Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala; Nature?537?97 |
|
|